As Per the Report, the Global Aptamers Market Size is valued at USD 207.7 million in 2019 and estimated to reach USD 448.8 million by the end of 2024 with a growing potential of 16.66 % during the forecast period 2019-2024.
MARKET OVERVIEW
Aptamers are oligonucleotides that bind to a target protein, lipid, or nucleic acid molecules with high specificity. Aptamers are generated quickly and applied in the inhibition, characterization of proteins and for specific detection. Aptamers can be used as pharmaceutical leads, functional proteomic levels with antibodies, detection reagents, and small molecules. Aptamers can be engineered to have higher specificity and affinity for a number of targets.
The enormous opportunities offered by the market for the key players are drug discovery, biomarker discovery, and diagnostics segments. The launch of Macugen, the first aptamer drug and the first diagnostic test for testing mycotoxins in grains has recognized the potential of aptamers in diagnostics and therapeutics. So, the global market for aptamers is expected to grow, backed by technological advancements with respect to selection processes and synthesis.
DRIVERS
The major factor driving the growth of the market are technological advancements, increasing R&D investments in pharmaceutical and biotechnology industries, low cost and high efficacy in binding to large molecules compared to antibodies and the patent expiration of systematic evolution of ligands by exponential enrichment technology (SELEX) will boost this market positively. Stringent regulations in the use of aptamers, Ethical issues of the aptamers that are obtained from the animals, slow in reaching the market place owing to regulatory hurdles are hindering the growth of the market.
REPORT COVERAGE
|
Report Metric |
Details |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 – 2024 |
|
Segments Analysed |
By Type, Application, End-User, and Region |
|
Regions Analysed |
North America (United States and Canada), Europe (UK, Spain, Germany, Italy, France and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, New Zealand, Rest of APAC), Latin America (Brazil, Argentina, Mexico and Rest of Latin America), Middle East and Africa |
|
Companies Analysed |
AM Biotechnologies, Aptagen, Aptamer Sciences Inc, Aptamer Solutions Ltd, Aptus Biotech S.L, Base Pair Biotechnologies Inc, NeoVentures Biotechnology Inc, SomaLogic Inc, TriLink BioTechnologies Inc, Vivonics, Inc., |
This research report on the Global Aptamers Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.
Aptamers Market - By Type:
On the basis of type, DNA Based Aptamers have the highest share in the market and XNA based Aptamers accounts to have the highest CAGR over the forecast period.
Aptamers Market - By Application:
Aptamers Market - By End User:
Regional Analysis:
North America dominates the global Aptamers market with the highest share followed by Europe, Asia - Pacific. Asia-Pacific is expected to account for the highest growth during the forecast period.
Companies leading the Global Aptamers Market profiled in the report are:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Peptide Aptamers
5.1.2 Nucleic Acid Aptamers
5.1.2.1 DNA-Based Aptamers
5.1.2.2 RNA-Based Aptamers
5.1.2.3 XNA-Based Aptamers
5.2 By Application
5.2.1 Therapeutics Development
5.2.2 Diagnostics
5.2.3 Research and Developments
5.3 By End Users
5.3.1 Pharmaceutical Companies
5.3.2 Bio-Pharmaceutical Companies
5.3.3 Academic and Research Centers
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 AM Biotechnologies
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Aptagen
8.3 Aptamer Sciences Inc.
8.4 Aptamer Solutions Ltd
8.5 Aptus Biotech S.L.
8.6 Base Pair Biotechnologies Inc
8.7 NeoVentures Biotechnology Inc.
8.8 SomaLogic Inc
8.9 TriLink BioTechnologies Inc
8.10 Vivonics, Inc
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
